modalities may be used, including radical cystectomy with or without neoadjuvant or adjuvant therapy, partial cystectomy, bladder-preserving approaches, and systemic therapy for advanced disease. Clinical trials investigating new treatments and further
Search Results
Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary P. Lovely, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Ian Parney, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie Weiss, Patrick Yung Wen, Nicole McMillian, and Anita M. Engh
retrospective and phase II studies showing positive outcomes in patients who had partial resection or biopsy. 28 – 30 These data showing clinical activity of PCV as adjuvant therapy for newly diagnosed low-grade gliomas prompted a multicenter phase III
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
the daily management of breast cancer patients? Eur J Cancer 2000 ; 36 : 1755 – 1761 . 40 Thor AD Berry DA Budman DR . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer . J Natl Cancer Inst 1998 ; 90
Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman
from low-risk patients and are not Table 1 Clinical Stage IA, NSGCT: Active Surveillance treated with adjuvant therapies. 16 , 32 Investigators at Princess Margaret Hospital followed 125 high-risk patients with the following protocol
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
treatment should not be compromised when decisions regarding breast reconstruction are made. Systemic Adjuvant Therapy After surgical treatment, adjuvant systemic therapy should be considered. The published results of the Early Breast Cancer
John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin
initially demonstrated in the mid-1980s, 3 or an aromatase inhibitor (AI). Beginning in 2005, recommendations from ASCO suggested that adjuvant therapy for postmenopausal women with HR+ breast cancer include an AI, either alone or in sequence after
Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults
involvement (69%), and without perineural invasion (96%) or lymphovascular invasion (94%). Most tumors were primarily resected (81%), and most adjuvant therapy was used in higher T-class cases (see supplemental eTable 2) . Of patients undergoing excision, 15
Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang
only a small portion of patients with stage II CRC, but is unnecessary in up to 70% of patients who might be cured by surgery alone. 5 , 6 According to a recent Cochrane systematic review, adjuvant therapy improves overall survival (OS) in <10% of
Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng
adjuvant therapy has been shown to negatively impact outcomes in stage III colon cancer 5 and stage I–III breast cancer. 6 Although a few studies have found a paradoxical relationship of shorter treatment initiation intervals correlating with
Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin
therapy referred to starting chemotherapy and RT within 14 days of each other, with the remainder designated as sequential. 25 , 26 Patients with an interval of >6 months from surgery to adjuvant therapy, or between adjuvant RT and chemotherapy, were
